CVS Health Delivers MBR Improvement: Is More Progress in the Cards?

CVS Health reported a Q3 2025 medical benefit ratio (MBR) of 92.8% versus 95.2% a year earlier, driven primarily by the non-recurrence of ~$1.1 billion in premium deficiency reserves recorded in Q3 2024 and $174 million of PDR utilization in H1 2025, plus favorable prior-period development and better Government business performance. Management said MBR was negatively affected by roughly 100 basis points from legacy provider liabilities and worsening individual exchange risk-adjustment expectations, and it reiterated full-year 2025 MBR guidance at approximately 91% at the low end of Health Care Benefits adjusted operating income guidance while taking a “thoughtful and prudent” view on medical cost trends; shares have risen ~27% over six months and analysts have been nudging 2025–2026 estimates higher.

Analysis

Market structure: CVS’s improved MBR to 92.8% (vs 95.2% prior) and management’s 91% full-year view reduce immediate underwriting concern but reveal a market split: integrated players with PBM/retail scale (CVS, COR as distributor) gain pricing and negotiating leverage while pure-exchange carriers and providers facing legacy liabilities lose margin. The ~100bp hit from provider liabilities and another ~100bp from exchange risk adjustment are economically meaningful — a 200bp swing on a $30B premium base equals ~$600M of profit swing annually, pressuring smaller carriers and hospital margin profiles.

Risk assessment: Tail risks include large retroactive provider settlements (>$500M), adverse CMS Part D rule changes, or a re-emergence of PDRs that would flip MBR >200bps within 3–12 months. Immediate (days) risk is earnings repricing; short-term (1–3 months) is guidance revisions and CMS/Rx policy updates; long-term (12–24 months) is IRA-driven Part D seasonality normalizing and exchange acuity trends. Hidden dependencies: CVS’s improvement leaned on non-repeatable PDR dynamics and prior-period development — durability depends on claims trend <3–4% annually and stable risk adjustment outcomes.

Trade implications: Tactical: establish a 2–3% long position in CVS (CVS) via shares or a 6–9 month bullish call spread (buy 6-month ATM, sell 20% OTM) to capture margin normalization; hedge with 0.5–1% notional 6-month puts. Add 1–2% long in Cencora (COR) for a 12–24 month thesis on distribution capacity expansion; pair long COR vs short MCK/ABC (1:1) to express share-gain. Avoid large exposure to pure exchange-focused insurers; consider short 1–2% positions in regional exchange-heavy names if risk-adjustment data deteriorates >150bps.

Contrarian angle: Consensus focuses on headline MBR improvement but underweights two persistent risks: legacy provider liabilities and IRA-induced Medicare seasonality. CVS’s 5-year forward P/S of 0.24 (industry 0.49) suggests the market still underprices upside if CVS sustains MBR ≤91% and converts retail synergies to >$1B incremental EBIT over 12–24 months; conversely, if provider liabilities re-accelerate >$500M, downside is asymmetric. Historical parallel: prior insurer reserve volatility (2015–2017) shows one-off reserve reversals can reverse multiple expansion within a quarter.

Key Decisions for Investors

• Establish a 2–3% long position in CVS (CVS) using either outright shares or a 6–9 month bull call spread (buy ATM, sell 20% OTM) to capture margin stabilization; size hedge with 0.5–1% notional 6-month puts. Trim or exit if company revises full‑year MBR guidance down by >150bps or announces additional PDRs >$300M.
• Establish a 1–2% long position in Cencora (COR) with a 12–24 month horizon to play distribution capacity expansion; sell a 9–12 month 25% OTM call to finance cost. Reduce position if COR delays planned national DC openings or reports capex slippage >25% of plan.
• Implement a pair trade: long COR (1.5%) vs short MCK or ABC (1.5%) to express distributor share shift; monitor relative EBITDA margin spread and unwind if the spread narrows <100bps within 6 months. Rebalance if COR’s utilization metrics don’t improve within 9 months.
• Maintain 1–2% protective short exposure (puts) on exchange-heavy regional insurers or buy puts on CVS (0.5–1% notional) as tail insurance ahead of 30–90 day CMS rule announcements; cut hedges if implied vol rises >50% or if CMS outcomes are neutral/positive.